Lipocine Inc. (LPCN) stock fell during pre-market trading. Here’s to know why?
Lipocine Inc. (NASDAQ: LPCN) stock declined by 1.55% at last close whereas the LPCN stock price plunged by 2.36% in the pre-market trading session. Lipocine is a clinical-stage biopharmaceutical business that uses its patented drug delivery technology to treat metabolic and endocrine diseases. >> 7 Top Picks for the Post-Pandemic Economy << What is happening? […]
Why Lipocine Inc. (LPCN) Stock plunged in premarket?
Clarus Therapeutics Defeats Lipocine’s (NASDAQ: LPCN) Patent Infringement Lawsuit On Summary JudgmentasFederal Circuit Judge William C. Bryson, granted Clarus’s motion for summary judgment against Lipocine, Inc. for failure to provide an appropriate written description of Lipocine’s asserted patent declarations. LPCN stock price plummeted adjacent to the news. Lipocine Inc. (LPCN) shares were falling -15.33% to […]
